Analysts Set Expectations for Cytosorbents FY2028 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – Equities researchers at HC Wainwright issued their FY2028 earnings estimates for Cytosorbents in a report issued on Thursday, April 3rd. HC Wainwright analyst S. Lee forecasts that the medical research company will post earnings per share of ($0.07) for the year. HC Wainwright currently has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ FY2029 earnings at ($0.05) EPS.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04. The business had revenue of $9.20 million for the quarter, compared to the consensus estimate of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.

CTSO has been the subject of several other reports. StockNews.com began coverage on shares of Cytosorbents in a research report on Thursday. They issued a “hold” rating for the company. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Cytosorbents has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Trading Down 2.0 %

NASDAQ CTSO opened at $0.97 on Friday. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61. The firm’s fifty day simple moving average is $1.07 and its 200-day simple moving average is $1.04. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $53.04 million, a PE ratio of -2.69 and a beta of 0.78.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors have recently made changes to their positions in the stock. Millennium Management LLC acquired a new stake in Cytosorbents during the 4th quarter worth approximately $30,000. Renaissance Technologies LLC increased its position in Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after acquiring an additional 8,400 shares during the period. Northern Trust Corp lifted its position in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares during the period. Raymond James Financial Inc. bought a new position in Cytosorbents in the fourth quarter valued at approximately $99,000. Finally, Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.